Overview

A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild Asthma and in Healthy Volunteers

Status:
Active, not recruiting

Trial end date:
2023-06-23

Target enrollment:

Participant gender:

Summary

This is a phase 1, first-in-human (FIH), multi-center, randomized, double-blind, placebo-controlled study of CSL311 in patients with mild asthma. The primary objective of this study is to assess the safety and tolerability of single ascending doses (SAD) and multiple ascending doses (MAD) of CSL311.

Phase:

Phase 1

Details

Lead Sponsor:

CSL Behring

Treatments:

Antibodies
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunoglobulins